Blog
About

9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial.

          Related collections

          Author and article information

          Journal
          J. Clin. Oncol.
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          1527-7755
          0732-183X
          Mar 20 2015
          : 33
          : 9
          Affiliations
          [1 ] Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France. carsten.denkert@charite.de.
          [2 ] Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France.
          Article
          JCO.2014.58.1967
          10.1200/JCO.2014.58.1967
          25534375
          © 2014 by American Society of Clinical Oncology.

          Comments

          Comment on this article